Navigating Biotech’s New Normal, Applying AI to Cas9 Enzymes, and Sequencing Generations Podcast Por  arte de portada

Navigating Biotech’s New Normal, Applying AI to Cas9 Enzymes, and Sequencing Generations

Navigating Biotech’s New Normal, Applying AI to Cas9 Enzymes, and Sequencing Generations

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

The seismic changes made by the current administration in the United States continue to impact the scientific community. The business news segment of this week’s episode covers the effects of job cuts on biotech, Roche’s manufacturing and R&D plans amid tariff threats, and shares an update on Eli Lilly’s diabetes pill. Also, in honor of DNA Day, we reminisce about how far the field has come since the discovery of the structure of DNA and the completion of the Human Genome Project. We also talk about today’s DNA-related advances that use machine learning to design tailored Cas9 proteins and multiple sequencing technologies to study mutation rates in four generations of the same family.


Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.


Listed below are links to the GEN stories referenced in this episode of Touching Base:


After Job Cuts, “We’re Entering a Very New Territory for Biotech.

By Alex Philippidis, GEN Edge, April 17, 2025


Roche Commits $50B to U.S. Manufacturing, R&D as Tariffs Loom

By Alex Philippidis, GEN Edge, April 22, 2025


StockWatch: Investors Hungry for Lilly after Diabetes Pill Aces Phase III Trial

By Alex Philippidis, GEN Edge, April 20, 2025

Machine Learning Engineers Bespoke Cas9 Enzymes for Gene Editing

By Fay Lin, PhD, GEN, April 22, 2025


Multi-Platform Sequencing Study of Four Generations Sheds Light on Mutation Rates

GEN, April 23, 2025

Hosted on Acast. See acast.com/privacy for more information.

adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones